<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18417822</article-id><article-id pub-id-type="pmc">2636122</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_3_215_40360</article-id><article-id pub-id-type="pmid">18417822 </article-id><article-categories><subj-group subj-group-type="heading"><subject>Symposium</subject></subj-group></article-categories><title-group><article-title>Medical management approach to infectious keratitis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Gokhale</surname><given-names>Nikhil S</given-names></name><degrees>MD</degrees></contrib></contrib-group><aff>Gokhale Eye Hospital and Eyebank, Anant Building, Gokhale Road (S),Dadar West, Mumbai-400 028, India</aff><author-notes><corresp id="cor1">Correspondence to Nikhil S. Gokhale, Gokhale Eye Hospital andEyebank, Anant Building, Gokhale Road (S), Dadar West, Mumbai -400 028, Maharashtra, India. Email: <email>gokhlay@vsnl.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>May-Jun</season><year>2008</year></pub-date><volume>56</volume><issue>3</issue><fpage>215</fpage><lpage>220</lpage><history><date date-type="received"><day>05</day><month>9</month><year>2007</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2008</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>This section provides guidelines on medical therapy of patients with infectious keratitis. In addition to initialempirical therapy, preferred medications, once the organisms responsible are isolated, are discussed. Atypicalmycobacterial keratitis following lasik is described. General guidelines for supportive therapy and follow-up,of these patients are presented. Clinical response to treatment and indications for intervention are discussed.Possible causes and approach to cases refractory to medical therapy are discussed.</p></abstract><kwd-group><kwd>Infectious keratitis</kwd><kwd>medical therapy</kwd></kwd-group></article-meta></front><body><p>Infectious keratitis is one of the major causes of avoidableblindness. Appropriate management could reduce the incidenceof severe visual loss and restrict corneal damage. Delay indiagnosing the nature of infection is one of the paramountfactors, which is responsible for inappropriate initial therapy.Standard guidelines, though available, are often not adheredto resulting in progressive ulceration. Emergence of drugresistance and availability of newer antimicrobials has madeit essential for us to update our knowledge and change ourtreatment guidelines. This article attempts to provide currentmedical management options for infectious keratitis.</p><sec sec-type=""><title>Management of Bacterial Ulcers</title><p>Bacterial keratitis should be treated as an ocular emergencydue to its rapid progression and disastrous complications.Empirical antibiotic therapy should be promptly started andthere are broadly two treatment options available [<xref ref-type="table" rid="T1">Table 1</xref>].Commercially available fluoroquinolone monotherapy ora combination therapy of fortified antibiotics (cefazolin 5%and tobramycin or gentamicin 1.4%). The frequency of dropsdepends upon the severity, but it is usual to start half-hourlydrops all through 24 h for most patients. A loading dose of adrop every 5 min for the first 30 min is used in severe ulcers.The frequency is reduced based on the clinical response.</p><p>The aminoglycoside antibiotics used in fortified drops aregentamicin and tobramycin. They give an excellent Gram-negative coverage and are also active against <italic>staphylococci</italic> andsome <italic>streptococci</italic> but not against <italic>pneumococci</italic>. They are howeverepitheliotoxic. Fortification is done by adding 80 mg/2 ml ofantibiotic injection to 5 ml of commercially available antibioticeye drops (0.3%) to get a concentration of 1.35%. The mostcommonly used cephalosporin in fortified drops is cefazolin.It gives good coverage for non-penicillinase producing Gram-positive bacteria. It is prepared by adding 5 ml of waterfor injection, to Injection Cefazolin 250 mg. The drops arerefrigerated and should be discarded if they discolor to yellowor after a week, whichever is earlier.</p><p>Initial treatment of suspected cases of microbial keratitiswith topical fortified antibiotics has long been the gold standardand the role for fluoroquinolone monotherapy continues to bedebated, although studies have shown both treatment optionsto be comparable.<xref ref-type="bibr" rid="ref1">1</xref>-<xref ref-type="bibr" rid="ref4">4</xref> Emerging resistance of<italic>Staphylococcus aureus,</italic><xref ref-type="bibr" rid="ref5">5</xref>-<xref ref-type="bibr" rid="ref7">7</xref><italic>Streptococcal species</italic><xref ref-type="bibr" rid="ref5">5</xref>-<xref ref-type="bibr" rid="ref7">7</xref> and<italic>Pseudomonas</italic><xref ref-type="bibr" rid="ref8">8</xref>-<xref ref-type="bibr" rid="ref9">9</xref> to the earliergeneration fluoroquinolones has raised concern over the use ofmonotherapy with these agents for suspected cases of bacterialkeratitis. This is especially true given the high rates of microbialkeratitis caused by Gram-positive organisms. Gatifloxacinand moxifloxacin [<xref ref-type="table" rid="T2">Table 2</xref>] demonstrate improved activityagainst Gram-positive pathogens, including <italic>Staphylococcusaureus</italic> and <italic>epidermidis</italic> and <italic>Streptococcus pneumoniae</italic>, as well asexcellent activity against atypical pathogens such as <italic>atypicalMycobacteria, Mycoplasma, Legionella, Chlamydia</italic> and theanaerobic <italic>Propionibacterium acnes</italic>. The aqueous penetrationof the newer quinolones is also significantly better. Aqueouspenetration was highest for moxifloxacin followed bygatifloxacin and was lowest for ciprofloxacin.<xref ref-type="bibr" rid="ref10">10</xref></p><p>It remains to be seen whether the relative reduction inGram-negative activity of these newer quinolones will allowmonotherapeutic application for routine management ofcorneal ulcers. Moxifloxacin was shown to be comparable toofloxacin and fortified antibiotics for treatment of bacterialkeratitis in a recent study.<xref ref-type="bibr" rid="ref11">11</xref> Gatifloxacin has been shown to besuperior to ciprofloxacin for management of bacterial keratitis.<xref ref-type="bibr" rid="ref12">12</xref>Gatifloxacin demonstrated a significantly better action thanciprofloxacin against Gram-positive cocci <italic>in vitro</italic> (<italic>P</italic> &#x0003c; 0.001)and the percentage of ulcers caused by these pathogensthat healed in the gatifloxacin group was significantly betterthan in the ciprofloxacin group (<italic>P</italic> = 0.009). Mean time takenfor healing of ulcer and the efficacy against Gram-negativebacteria did not significantly differ between the two groups.The authors suggest that gatifloxacin may be a preferredalternative to ciprofloxacin as the first-line monotherapy inbacterial keratitis.</p><p>Although controversial, it is the opinion of many authoritiesthat results of Gram&#x02032;s staining should not be used to alter theinitial therapy started.<xref ref-type="bibr" rid="ref13">13</xref> It is recommended to initiate therapywith a broad-spectrum regimen<xref ref-type="bibr" rid="ref14">14</xref> and change it based on theclinical response and culture results.</p><p>Avascularity of cornea, as well as poor penetration of thedrug in the stroma requires frequent application of topicalantibiotics and is the basis for the loading dose concept. It isessential that minimum inhibitory concentration (MIC) of thedrug be achieved at the site of infection. Drug concentrationsachieved in the eye may be above the serum MIC levels and thismay explain a good clinical response to an antibiotic to whichthe organism is not very sensitive <italic>in vitro</italic>. In these situations,a change in therapy is not warranted.<xref ref-type="bibr" rid="ref15">15</xref> In a nutshell, clinicalresponse should be the first guideline of therapy, althoughin non-healing ulcer, <italic>in vitro</italic> sensitivity should be given dueattention. It is also important that <italic>in vitro</italic> sensitivity should becorrelated with <italic>in vivo</italic> response before considering change intherapy, as inadequate frequency, poor penetration, stromallysis, and necrotic debris covering the site of infection can bethe causes of non-responsiveness of ulcer to therapy.</p><p>Subconjunctival antibiotics<xref ref-type="bibr" rid="ref16">16</xref> are associated with pain,redness, patient apprehension, risk of globe perforationand failure to provide enhanced corneal levels of antibioticcompared to drops. They are no longer advisable for routinemanagement of corneal infections. Oral or parenteral antibioticshave been shown to be of no benefit<xref ref-type="bibr" rid="ref17">17</xref> and are indicated only inulcers with perforation, scleral involvement or endophthalmitis.Gonococcal infections require systemic ceftriaxone.</p></sec><sec sec-type=""><title>Other Antibiotics</title><p><list list-type="order"><list-item><p><bold>Amikacin</bold>  (40-100 mg/ml): It is useful for infections dueto Gram-negative organisms resistant to tobramycin andgentamicin. It is also used in infections due to <italic>atypicalmycobacteria</italic>  and <italic>Nocardia</italic>.</p></list-item><list-item><p><bold>Vancomycin</bold> (50 mg/ml): It is useful for Gram-positiveinfections including <italic>methicillin-resistant staphylococci</italic>.Empirical use is not recommended since it will escalatedrug resistance.</p></list-item><list-item><p><bold>Methicillin</bold> (50 mg/ml): It is useful for penicillinaseproducing <italic>Staphylococci</italic>.</p></list-item><list-item><p><bold>Cotrimoxazole</bold> (Trimethoprim 16 mg/ml + sulfamethoxazole80 mg/ml): It is recommended for <italic>Nocardia</italic> infections. Theintravenous preparation is used directly as eye drops.</p></list-item><list-item><p><bold>Anti-pseudomonas antibiotics:</bold> Piperacillin (7 mg/ml),ceftazidime (50 mg/ml), cefoperazone and imipenem maybe used in multidrug-resistant infections.</p></list-item><list-item><p><bold>Clarithromycin</bold> (10-40 mg/ml): Useful in atypicalmycobacterial infections.</p></list-item></list></p></sec><sec sec-type=""><title>Atypical Mycobacterial Infections and Post-lasik Infectious Keratitis</title><p>Atypical mycobacterial infections are being seen and diagnosedmore often because of more awareness and better microbiologytechniques. Though they have been seen in patients of infectiouskeratitis and in post-cataract wound infections, the clustersof mycobacterial outbreaks following lasik have been moreserious. All cases of suspected infectious keratitis followinglasik require a flap lift and microbiologic evaluation.</p><p>The traditional drug of choice for the treatment ofmycobacterial keratitis has been the aminoglycoside amikacin.However, the non-response rate to amikacin may be as high as 60%, likely due to poor penetration through intact epithelium.Ciprofloxacin could be used for isolates resistant to amikacin. <italic>Invitro</italic> data suggests that <italic>M. fortuitum</italic> is more sensitive to amikacinand ciprofloxacin than <italic>M. chelonae</italic>.<xref ref-type="bibr" rid="ref18">18</xref> Another report suggestedgood <italic>in vitro</italic> antimicrobial activity of amikacin, clarithromycin,imipenem and ciprofloxacin against <italic>M. chelonae</italic>. However, nosynergistic effects were demonstrated for combinations of anaminoglycoside with other effective drugs.<xref ref-type="bibr" rid="ref19">19</xref> Though the fourthgeneration quinolones are known to be effective, a change insensitivity patterns has also to be kept in mind. Seventeenout of 18 mycobacterial isolates (3 <italic>M. abscessus</italic> and 14 <italic>M.chelonae</italic>) recovered from post-lasik infectious keratitis casesin Brazil were resistant to ciprofloxacin, ofloxacin, gatifloxacinand moxifloxacin.<xref ref-type="bibr" rid="ref20">20</xref> Topical and oral macrolides, such asclarithromycin (10-40 mg/ml) and azithromycin (2 mg/ml) arealso effective in these cases.<xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></p><p>Steroids may yield an initial clinical improvement, but theoverall course is worsened due to suppression of cell-mediatedimmunity, an integral part of combating mycobacterialdisease.<xref ref-type="bibr" rid="ref21">21</xref></p><p>Despite intensive topical treatment, post-lasik mycobacterialkeratitis frequently does not respond to medical therapy. Poordrug penetration and sequestration of the organism frequentlynecessitate flap amputation. Penetrating keratoplasty mayalso be required for extirpation of the organism or for visualrehabilitation.</p></sec><sec sec-type=""><title>Supportive Therapy and Follow-up for Corneal Infections</title><p>All patients require frequent and close observationuntil they start responding to treatment. Admission tohospital is advisable for patients where compliance withmedical therapy or follow-up is an issue. Cycloplegics,antiglaucoma medications, and analgesics are used asrequired. Corticosteroids as anti-inflammatory are bestavoided, until the infection is completely eradicated or undercontrol. Non-steroidal anti-inflammatory drugs are also betterto avoid in patients with corneal ulceration due to the risk ofcorneal melting and perforation.</p><p>Signs of improvement are:</p><p><list list-type="order"><list-item><p>Stabilization and no progression</p></list-item><list-item><p>Reduced activity at infiltrate margins/blunting of ulceredges</p></list-item><list-item><p>Reduction in adjacent stromal inflammatory reaction andanterior chamber inflammation</p></list-item><list-item><p>Resolution of infiltration and progressive healing ofepithelial defect.</p></list-item></list></p><p>If a patient with negative scrape report continues to worsen,non-infectious ulcers or infections due to other organismsmust be considered. A corneal biopsy may help in deep-seatedinfections where a surface scrape is likely to be negative.</p><p>Progressive corneal thinning or perforations less than2 mm can be managed with cyanoacrylate tissue adhesive andbandage contact lens application. Larger perforations requirea therapeutic penetrating keratoplasty. Conjunctival flaps mayhelp selected cases of refractory ulceration.</p></sec><sec sec-type=""><title>Management of Fungal Ulcers</title><p>Natamycin 5% suspension is the first choice for treatment offilamentous fungal keratitis<xref ref-type="bibr" rid="ref23">23</xref>[<xref ref-type="table" rid="T3">Table 3</xref>]. Surfacedebridement helps to remove slough and reduce load of infection. It alsoenhances the drug penetration. Drops are used every half to onehourly initially and tapered as per the clinical response. Responseto treatment in fungal infections is very slow and completeresolution often may require 4-8 weeks of treatment.</p><p>Amphotericin B is particularly effective against yeasts but lesseffective against filamentous fungi; it is therefore the first agentof choice against yeasts. Amphotericin B (0.15%) drops can beconsidered alone or in combination with natamycin in refractorycases; however, their penetration through an intact epithelium isless than natamycin.<xref ref-type="bibr" rid="ref24">24</xref> Intracameral 5-10 &#x000b5;g amphotericin B hasalso been used<xref ref-type="bibr" rid="ref25">25</xref> successfully in patients refractory to topical andoral antifungals. Amphotericin B is available as a 50-mg injection.Drops are prepared by adding 10 ml water for injection to the vialto get a stock solution (5 mg/ml). 3.5 ml of water for injection isadded to 1.5 ml of this stock solution to get 5 ml of 0.15% drops,which can be dispensed. The drops should be refrigerated andshould not be exposed to light. The drops should be inspectedat each visit for any turbidity, which may indicate contaminationor drug precipitation.</p><p>The azoles and fluocytosine are generally employedas alternative agents for advanced ulcers or for ulcers notresponding to polyenes. Experimental models suggest anantagonism<xref ref-type="bibr" rid="ref26">26</xref> between amphotericin B and imidazoles and somedo not recommend this combination, although clinical evidencehas been contradictory. Topically applied, the imidazoles havepoor corneal penetration, and so they are more effective intreating superficial infections especially due to <italic>Aspergillus</italic>.Topical itraconazole 1%, clotrimazole 1%, ketoconazole 2%,econazole 2%, and miconazole 1% have also been used for fungalkeratitis. A study showed that 2% econazole was as effective asnatamycin 5%;<xref ref-type="bibr" rid="ref27">27</xref> however, the concurrent use of 5% natamycinand 2% econazole<xref ref-type="bibr" rid="ref28">28</xref> did not offer additional benefits overmonotherapy with 5% natamycin alone for the management offungal keratitis. Natamycin 5% has been shown to be superior toitraconazole 2%<xref ref-type="bibr" rid="ref29">29</xref> for filamentous fungal keratitis. Fluconazolehas high corneal penetration and reaches therapeutic corneallevels when given orally. It is effective against <italic>Candida</italic> and alsouseful against <italic>Aspergillus</italic>. Its clinical role in filamentous fungalkeratitis is yet to be precisely defined; however, it could beconsidered in patients with deep fungal keratitis.</p><p>Patients, with deep infiltrates, with exudates in theanterior chamber, are often refractory to medical therapy. Oralitraconazole 100 mg twice daily or ketoconazole 200 mg twicedaily can be added in these cases. Liver function tests need tobe done before and during the treatment.</p><p>Voriconazole has the broadest spectrum of the azoleantifungals and has good intraocular penetration after oraladministration.<xref ref-type="bibr" rid="ref30">30</xref> Voriconazole is a new, promising therapy forfungal keratitis that is refractory to standard antifungal agents.It is used orally 200 mg twice daily and as drops (0.1-1%).<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></p><p>Newer agents<xref ref-type="bibr" rid="ref33">33</xref> such as triazoles (posaconazole andravuconazole), echinocandins, sodarin derivatives and thenikkomycins might improve the treatment of fungal keratitisin future.</p><p><italic>In vitro</italic> <italic>E</italic>-test<xref ref-type="bibr" rid="ref34">34</xref> for assessing antifungal drugsusceptibility may provide information for choosing antifungal agents totreat fungal keratitis.</p></sec><sec sec-type=""><title>Supportive Therapy and Follow-up</title><p>This would be similar to bacterial ulcers as mentioned earlier.Corticosteroids are contraindicated in fungal keratitis. About20% of fungal ulcers are refractory to medical therapy<xref ref-type="bibr" rid="ref35">35</xref> andcontinue to worsen despite maximal medical therapy. This maybe due to the deeper penetration of fungal filaments, poor drugpenetration or drug resistance. This subset of patients needsto be identified early and should undergo an early therapeuticpenetrating keratoplasty. Delay in surgery often leads to scleralinvolvement, endophthalmitis and eventual loss of the eye.</p></sec><sec sec-type=""><title>Management of Acanthamoeba Keratitis</title><p>It is difficult to diagnose and treat <italic>Acanthamoeba</italic> keratitis.Chlorhexidine and polyhexamethylene biguanide (PHMB) arethe most effective<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref> against trophozoites andcysts and are recommended as the first line of therapy [<xref ref-type="table" rid="T4">Table 4</xref>]. These dropsare commercially not available; however, they can be obtainedin India from tertiary care ophthalmic institutes on request.Medications have to be used for a long time after clinicalresolution of infection to prevent relapses. This is because ofthe drugs being less effective against the cystic forms. Routineuse of topical steroids<xref ref-type="bibr" rid="ref38">38</xref> is controversial though its use has beenrecommended specifically for limbitis, scleritis, and uveitis.</p></sec><sec sec-type=""><title>Management of Microsporidiosis</title><p>Fumagillin<xref ref-type="bibr" rid="ref39">39</xref>-<xref ref-type="bibr" rid="ref41">41</xref> 10 mg/ml suspension is veryeffective in <italic>microsporidial</italic> keratoconjunctivitis. In refractory cases oralalbendazole,<xref ref-type="bibr" rid="ref42">42</xref> oral itraconazole<xref ref-type="bibr" rid="ref43">43</xref> has been usedsuccessfully. Propamidine drops have also been used in some cases.</p></sec><sec sec-type=""><title>Management of Viral Infections</title><p>We shall restrict our discussion to management of <italic>Herpessimplex</italic> and <italic>Herpes zoster</italic> infections.</p><sec><title>Herpes Simplex virus keratitis</title><sec><title>Dendritic epithelial disease without stromal involvement</title><p>Infected epithelial cells are debrided with a sterile cotton tippedapplicator and acyclovir 3% eye ointment is started five timesa day. Antivirals are used for 2-3 weeks. Topical steroids arecontraindicated in infectious epithelial disease.</p></sec><sec><title>Epithelial trophic ulceration (metaherpetic)</title><p>Intensive lubrication with preservative-free tear substitutes isusually successful in these patients. Antivirals have no role.Steroids and non-steroidal anti-inflammatory medications arebest avoided in the presence of an epithelial defect. However, inthe presence of stromal inflammation, diluted steroids could beused with extreme caution. Bandage contact lenses and amnioticmembrane grafting could also be tried in refractory cases. Severecases may require a tarsorrhaphy or a conjunctival flap. In thepresence of progressive stromal melting or a small perforation,cyanoacrylate tissue adhesive is useful and allows one topostpone a therapeutic keratoplasty in an inflamed eye.</p></sec><sec><title>Stromal keratitis</title><p>The herpetic eye disease study (HEDS) concluded that acombination of topical steroids and antivirals reduces thepersistence or progression of stromal inflammation andshortens the duration of stromal keratitis.<xref ref-type="bibr" rid="ref33">33</xref> Additional use oforal acyclovir was found to be of no benefit.<xref ref-type="bibr" rid="ref45">45</xref> Steroids oncestarted need to be tapered very slowly and under observationfor recurrent inflammation.</p></sec><sec><title>Trabeculitis and iridocyclitis</title><p>Topical steroid and antiviral combination is recommended.HEDS also recommends additional oral acyclovir foriridocyclitis.<xref ref-type="bibr" rid="ref46">46</xref></p></sec><sec><title>Recurrent ocular disease and oral prophylaxis</title><p>The HEDS study conclusively proved that oral acyclovir 400 mgtwice daily reduces the recurrence of herpetic eye disease.<xref ref-type="bibr" rid="ref47">47</xref>This should be considered in patients at risk of visual loss dueto repeated HSV stromal keratitis.</p></sec></sec><sec><title>Herpes zoster</title><p>Herpes zoster ophthalmicus (HZO) should be treated with oralacyclovir 800 mg five times a day for 7-10 days, ideally initiatedwithin 72 h of the onset of symptoms.</p><p>Newer antivirals can also be used for HZO. Famcicloviris more bioavailable when given orally than acyclovir and itsactive metabolite penciclovir triphosphate has an intracellularhalf-life nearly 10 times that of acyclovir. Recommendeddosage is 500 mg/day for 7 days. Valacyclovir is a prodrug of acyclovir that is more bioavailable orally. It achieves threetimes higher plasma levels comparable to those achieved withintravenous acyclovir.<xref ref-type="bibr" rid="ref48">48</xref> Recommended dose is 1000 mg threetimes a day for 7-10 days. Both famciclovir and valacyclovirappear to be superior to acyclovir in reducing the duration ofzoster-associated pain.<xref ref-type="bibr" rid="ref49">49</xref></p><p>Systemic corticosteroids reduce pain and improve patientfunctioning. However, they carry the risk of causing disseminatedviral infection especially in the immunocompromised andshould be used with caution.</p><p>Topical steroids are useful for reducing corneal and scleralinflammation and iridocyclitis. Topical antivirals are usuallynot employed for zoster keratitis.</p><p>Neurotrophic ulceration is a major complication ofHZO. Preservative-free lubricants, bandage contact lens,tarsorrhaphy, amniotic membrane grafts, and conjunctivalflaps may be required to treat these patients. Severe thinningor perforation may require cyanoacrylate tissue adhesive or atherapeutic keratoplasty.</p></sec></sec><sec sec-type=""><title>Approach to Non-healing Infectious Corneal Ulcers</title><p>Any corneal ulcer not responding to appropriate treatment overa period of 2-3 weeks could be labeled as a non-healing ulcer.It could be infectious, sterile, immune mediated or due to acombination of these processes. There could be associated ocularor systemic problems contributing to the ulcerative process.</p></sec><sec sec-type=""><title>Wrong Line of Therapy</title><p>It is not unusual to see fungal ulcers being treated asbacterial and vice versa. This is because it is often difficultfor ophthalmologists to distinguish the nature of infectionclinically and due to our inertia (rather than a lack of facilities)that stops us from doing microbial work-up. Wrong or negativemicrobiology reports, due to various reasons, also complicatethe situation. Improving clinical skills and using propermicrobiologic techniques can improve management of cornealulcers. Referral to centers equipped with a cornea specialist andgood laboratory support in refractory cases is advisable.</p><sec><title>Inadequate therapy</title><p>Despite correctly diagnosing the nature of infection, a wrongchoice of antimicrobial drops or an inadequate frequency of usecould also cause a lack of expected improvement. Poor drugpenetration could also be an important cause of poor response.Routine use of combination therapies to encompass multipleorganisms should be avoided, as it not only reduces clinicalefficacy but also increases toxicity.</p></sec><sec><title>Drug resistance</title><p>Increasing resistance of micro-organisms to antimicrobials isbeing reported worldwide. In hospital-acquired infections,infections in hospital personnel and infections in eyes withchronic ocular surface disease, resistant Gram-negativeand methicillin-resistant <italic>staphylococci</italic> are known to causekeratitis. Empiric use of higher generation antimicrobials inthese situations may be warranted. Microbiologic evaluationand <italic>in vitro</italic> sensitivity data are a must and help to guidetherapy. Similarly, fungal ulcers are often refractory to allavailable antifungals. In these situations, an early therapeutickeratoplasty is the only eye-saving option.</p></sec><sec><title>Toxicity</title><p>Continued aggressive antimicrobial therapy even after theinfection has responded could be a cause of non-healing afterthe initial favorable response. Drug toxicity could by itself delayepithelization and cause more stromal thinning.</p><p>All patients with non-healing ulcers need to be re-evaluatedto check for corneal sensations, tear film problems, lid andlash problems and missed foreign body. A systemic work-upis indicated in patients with sterile corneal melting to rule outcollagen disease.</p></sec></sec></body><back><fn-group><fn><p>Source of Support: Nil</p></fn><fn><p>Conflict of Interest: None declared</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02032;Brien</surname><given-names>TP</given-names></name><name><surname>Maguire</surname><given-names>MG</given-names></name><name><surname>Fink</surname><given-names>NE</given-names></name><name><surname>Alfonso</surname><given-names>E</given-names></name><name><surname>McDonnell</surname><given-names>P</given-names></name></person-group><article-title>Efficacy of ofloxacin versus cefazolin and tobramycin in the therapy for bacterial keratitis: Report from the BacterialKeratitis Study Research Group</article-title><source>Arch Ophthalmol</source><year>1995</year><volume>113</volume><fpage>1257</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">7575256</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyndiuk</surname><given-names>RA</given-names></name><name><surname>Eiferman</surname><given-names>RA</given-names></name><name><surname>Caldwell</surname><given-names>DR</given-names></name><name><surname>Rosenwaser</surname><given-names>GO</given-names></name><name><surname>Santos</surname><given-names>CI</given-names></name><name><surname>Katz</surname><given-names>HR</given-names></name><etal/></person-group><article-title>Comparison of ciprofloxacin ophthalmic solution0.3% to fortified tobramycin-cefazolin in treating bacterial cornealulcers. Comparison of ciprofloxacin ophthalmic solution 0.3% tofortified tobramycin-cefazolin in treating bacterial corneal ulcers</article-title><source>Ophthalmology</source><year>1996</year><volume>103</volume><fpage>1854</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">8942881</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><collab>The Ofloxacin Study Group</collab><article-title>Ofloxacin montherapy for the primary treatment of microbial keratitis: A double-masked, randomized, controlled trialwith conventional dual therapy</article-title><source>Ophthalmology</source><year>1997</year><volume>104</volume><fpage>1902</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9373124</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panda</surname><given-names>A</given-names></name><name><surname>Ahuja</surname><given-names>R</given-names></name><name><surname>Sastry</surname><given-names>SS</given-names></name></person-group><article-title>Comparison of topical 0.3% ofloxacinwith fortified tobramycin plus cefazolin in the treatment of bacterialkeratitis</article-title><source>Eye</source><year>1999</year><volume>13</volume><fpage>744</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">10707137</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>MH</given-names></name><name><surname>Kowalski</surname><given-names>RP</given-names></name><name><surname>Gordon</surname><given-names>YJ</given-names></name></person-group><article-title>Emerging fluoroquinolone resistance in bacterial keratitis: A 5-year review</article-title><source>Ophthalmology</source><year>1999</year><volume>106</volume><fpage>1313</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10406613</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrakis</surname><given-names>G</given-names></name><name><surname>Alfonso</surname><given-names>EC</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name></person-group><article-title>Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones</article-title><source>Ophthalmology</source><year>2000</year><volume>107</volume><fpage>1497</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">10919897</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knauf</surname><given-names>HP</given-names></name><name><surname>Silvany</surname><given-names>R</given-names></name><name><surname>Southern</surname><given-names>PM</given-names><suffix>Jr</suffix></name><name><surname>Knauf</surname><given-names>HP</given-names></name><name><surname>Silvany</surname><given-names>R</given-names></name><name><surname>Southern</surname><given-names>PM</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Susceptibility of corneal and conjunctival pathogens to ciprofloxacin</article-title><source>Cornea</source><year>1996</year><volume>15</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">8907383</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>P</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Rao</surname><given-names>GN</given-names></name></person-group><article-title>Ciprofloxacin resistant Pseudomonas keratitits</article-title><source>Ophthalmology</source><year>1999</year><volume>106</volume><fpage>1319</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">10406614</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunimoto</surname><given-names>DY</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>P</given-names></name><name><surname>Rao</surname><given-names>GN</given-names></name></person-group><article-title>In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin: Emerging resistance</article-title><source>Ophthalmology</source><year>1999</year><volume>106</volume><fpage>80</fpage><lpage>5</lpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>R</given-names></name><name><surname>Donnenfeld</surname><given-names>ED</given-names></name><name><surname>Perry</surname><given-names>HD</given-names></name><name><surname>Snyder</surname><given-names>RW</given-names></name><name><surname>Nedrud</surname><given-names>C</given-names></name><name><surname>Stein</surname><given-names>J</given-names></name><etal/></person-group><article-title>Penetration of topically applied Gatifloxacin 0.3%,Moxifloxacin 0.5% and Ciprofloxacin 0.3% into the aqueous humor</article-title><source>Ophthalmology</source><year>2005</year><volume>112</volume><fpage>466</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15745775</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constantinou</surname><given-names>M</given-names></name><name><surname>Daniell</surname><given-names>M</given-names></name><name><surname>Snibson</surname><given-names>GR</given-names></name><name><surname>Vu</surname><given-names>HT</given-names></name><name><surname>Taylor</surname><given-names>HR</given-names></name></person-group><article-title>Clinical efficacy of Moxifloxacin in the treatment of bacterial keratitis</article-title><source>Ophthalomolgy</source><year>2007</year><volume>114</volume><fpage>1622</fpage><lpage>9</lpage></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parmar</surname><given-names>P</given-names></name><name><surname>Salman</surname><given-names>A</given-names></name><name><surname>Kalavathy</surname><given-names>CM</given-names></name><name><surname>Kaliamurthy</surname><given-names>J</given-names></name><name><surname>Prasanth</surname><given-names>DA</given-names></name><name><surname>Thomas</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Comparison of topical Gatifloxacin 0.3% and Ciprofloxacin 0.3% for the treatment of bacterialkeratitis</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>141</volume><fpage>282</fpage><pub-id pub-id-type="pmid">16458681</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Arffa</surname><given-names>RC</given-names></name></person-group><article-title>Infectious ulcerative keratitis: Bacterial</article-title><source>Grayson&#x02032;s diseases of the cornea</source><year>1991</year><publisher-loc>St. Louis</publisher-loc><publisher-name>Mosby Year Book</publisher-name><fpage>163</fpage><lpage>98</lpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLeod</surname><given-names>SD</given-names></name><name><surname>LaBree</surname><given-names>LD</given-names></name><name><surname>Tayyanipour</surname><given-names>R</given-names></name><name><surname>Flowers</surname><given-names>CW</given-names></name><name><surname>Lee</surname><given-names>PP</given-names></name><name><surname>McDonnell</surname><given-names>PJ</given-names></name></person-group><article-title>The importance of initial management in the treatment of severe infectious corneal ulcers</article-title><source>Ophthalmology</source><year>1995</year><volume>102</volume><fpage>1943</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9098300</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ormerod</surname><given-names>LD</given-names></name><name><surname>Heseltine</surname><given-names>PN</given-names></name><name><surname>Alfonso</surname><given-names>E</given-names></name><name><surname>Becker</surname><given-names>MI</given-names></name><name><surname>Kenyon</surname><given-names>KR</given-names></name><name><surname>Baerveldt</surname><given-names>G</given-names></name><etal/></person-group><article-title>Gentamicin resistant pseudomonal infection: Rationale for a redefinition of ophthalmic antimicrobialsensitivities</article-title><source>Cornea</source><year>1989</year><volume>8</volume><fpage>195</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2787230</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baum</surname><given-names>J</given-names></name><name><surname>Barza</surname><given-names>M</given-names></name></person-group><article-title>Topical vs subconjunctival treatment of bacterial corneal ulcers</article-title><source>Ophthalmology</source><year>1979</year><volume>87</volume><fpage>710</fpage><lpage>6</lpage></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>SD</given-names></name><name><surname>Sarff</surname><given-names>LD</given-names></name><name><surname>Hyndiuk</surname><given-names>RA</given-names></name></person-group><article-title>Comparison of therapeutic routes in experimental Pseudomonas keratiits</article-title><source>Am J Ophthalmol</source><year>1979</year><volume>87</volume><fpage>710</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">443343</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>FR</given-names></name><name><surname>Luh</surname><given-names>KT</given-names></name></person-group><article-title>Topical ciprofloxacin for treating nontuberculous mycobacterial keratitis</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>269</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">9479286</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>FR</given-names></name><name><surname>Chang</surname><given-names>SC</given-names></name><name><surname>Luh</surname><given-names>KT</given-names></name><name><surname>Hung</surname><given-names>PT</given-names></name></person-group><article-title>The antimicrobial susceptibility of Mycobacterium chelonae isolated from corneal ulcer</article-title><source>Curr Eye Res</source><year>1997</year><volume>16</volume><fpage>1056</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">9330859</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofling-Lima</surname><given-names>AL</given-names></name><name><surname>de Freitas</surname><given-names>D</given-names></name><name><surname>Sampaio</surname><given-names>JL</given-names></name><name><surname>Leao</surname><given-names>SC</given-names></name><name><surname>Contarini</surname><given-names>P</given-names></name></person-group><article-title>In vitro activity of fluoroquinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectiouskeratitis after LASIK in Brazil</article-title><source>Cornea</source><year>2005</year><volume>24</volume><fpage>730</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">16015094</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>JG</given-names></name><name><surname>Huang</surname><given-names>AJ</given-names></name><name><surname>Pflugfelder</surname><given-names>SC</given-names></name><name><surname>Alfonso</surname><given-names>EC</given-names></name><name><surname>Forster</surname><given-names>RK</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name></person-group><article-title>Nontuberculous mycobacterial keratitis in South Florida</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>1652</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9754173</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>NS</given-names></name><name><surname>Torres</surname><given-names>MF</given-names></name><name><surname>Winthrop</surname><given-names>KL</given-names></name><name><surname>Bruckner</surname><given-names>DA</given-names></name><name><surname>Heidemann</surname><given-names>DG</given-names></name><name><surname>Calvet</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Cluster of Mycobacterium chelonae keratitis cases following laser in-situ keratomileusis</article-title><source>Am J Ophthal</source><year>2001</year><volume>132</volume><fpage>819</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">11730644</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02032;Day</surname><given-names>DM</given-names></name><name><surname>Robinson</surname><given-names>RD</given-names></name><name><surname>Head</surname><given-names>WS</given-names></name></person-group><article-title>Efficacy of anti-fungal agents in the cornea, I: A comparative study</article-title><source>Invest Ophthalmol Vis Sci</source><year>1983</year><volume>24</volume><fpage>1098</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">6874272</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02032;Day</surname><given-names>DM</given-names></name><name><surname>Head</surname><given-names>WS</given-names></name><name><surname>Robinson</surname><given-names>RD</given-names></name><name><surname>Clanton</surname><given-names>JA</given-names></name></person-group><article-title>Corneal penetration of topical amphotericin B and natamycin</article-title><source>Curr Eye Res</source><year>1986</year><volume>5</volume><fpage>877</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">3490954</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushik</surname><given-names>S</given-names></name><name><surname>Ram</surname><given-names>J</given-names></name><name><surname>Brar</surname><given-names>GS</given-names></name><name><surname>Jain</surname><given-names>AK</given-names></name><name><surname>Chakraborti</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name></person-group><article-title>Intracameral amphotericn B: Initial experience in severe keratomycosis</article-title><source>Cornea</source><year>2001</year><volume>20</volume><fpage>715</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11588423</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brajtburg</surname><given-names>J</given-names></name><name><surname>Kobayashi</surname><given-names>D</given-names></name><name><surname>Medoff</surname><given-names>G</given-names></name><name><surname>Kobayashi</surname><given-names>GS</given-names></name></person-group><article-title>Antifungal action of amphoteracin B in combination with other polyene or imidazole antibiotics</article-title><source>J Infect Dis</source><year>1982</year><volume>146</volume><fpage>138</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">6286784</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prajna</surname><given-names>NV</given-names></name><name><surname>John</surname><given-names>RK</given-names></name><name><surname>Nirmalan</surname><given-names>PK</given-names></name><name><surname>Lalitha</surname><given-names>P</given-names></name><name><surname>Srinivasan</surname><given-names>M</given-names></name></person-group><article-title>A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungalkeratitis</article-title><source>Br J Ophthalmol</source><year>2003</year><volume>87</volume><fpage>1235</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">14507756</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prajna</surname><given-names>NV</given-names></name><name><surname>Nirmalan</surname><given-names>PK</given-names></name><name><surname>Mahalakshmi</surname><given-names>R</given-names></name><name><surname>Lalitha</surname><given-names>P</given-names></name><name><surname>Srinivasan</surname><given-names>M</given-names></name></person-group><article-title>Concurrent use of 5% natamycin and 2% econazole for the management of fungal keratitis</article-title><source>Cornea</source><year>2004</year><volume>23</volume><fpage>793</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15502480</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalavathy</surname><given-names>CM</given-names></name><name><surname>Parmar</surname><given-names>P</given-names></name><name><surname>Kaliamurthy</surname><given-names>J</given-names></name><name><surname>Philip</surname><given-names>VR</given-names></name><name><surname>Ramalingam</surname><given-names>MD</given-names></name><name><surname>Jesudasan</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungalkeratitis</article-title><source>Cornea</source><year>2005</year><volume>24</volume><fpage>449</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">15829804</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haripasad</surname><given-names>SM</given-names></name><name><surname>Mieler</surname><given-names>WF</given-names></name><name><surname>Holz</surname><given-names>ER</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>JE</given-names></name><name><surname>Chi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Determination of vitreous, aqueous and plasma concentration of orally administered voriconazole inhumans</article-title><source>Arch Ophthalmol</source><year>2004</year><volume>122</volume><fpage>42</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">14718293</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunya</surname><given-names>VY</given-names></name><name><surname>Hammersmith</surname><given-names>KM</given-names></name><name><surname>Rapuano</surname><given-names>CJ</given-names></name><name><surname>Ayres</surname><given-names>BD</given-names></name><name><surname>Cohen</surname><given-names>EJ</given-names></name></person-group><article-title>Topical and oral voriconazole in the treatment of fungal keratitis</article-title><source>Am J Ophthalmol</source><year>2007</year><volume>143</volume><fpage>151</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">17188052</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jhanji</surname><given-names>V</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Mannan</surname><given-names>R</given-names></name><name><surname>Titiyal</surname><given-names>JS</given-names></name><name><surname>Vajpayee</surname><given-names>RB</given-names></name></person-group><article-title>Management of tunnel fungal infection with voriconazole</article-title><source>J Cataract Refract Surg</source><year>2007</year><volume>33</volume><fpage>915</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17466872</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>EJ</given-names></name></person-group><article-title>Investigational antifungal agents</article-title><source>Pharmacotherapy</source><year>2001</year><volume>21</volume><fpage>165S</fpage><lpage>74S</lpage><pub-id pub-id-type="pmid">11501989</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>WY</given-names></name><name><surname>Yao</surname><given-names>YF</given-names></name><name><surname>Zhu</surname><given-names>YF</given-names></name><name><surname>Zhang</surname><given-names>YM</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Jin</surname><given-names>YQ</given-names></name><etal/></person-group><article-title>Fungal spectrum identified by a new slide culture and in vitro drug susceptibility using Etest in fungalkeratitis</article-title><source>Curr Eye Res</source><year>2005</year><volume>30</volume><fpage>1113</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">16354625</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forster</surname><given-names>RK</given-names></name><name><surname>Rebell</surname><given-names>G</given-names></name></person-group><article-title>Therapeutic surgery in failures of medical treatment for fungal keratitis</article-title><source>Br J Ophthalmol</source><year>1975</year><volume>59</volume><fpage>366</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">1103963</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elder</surname><given-names>MJ</given-names></name><name><surname>Kilvington</surname><given-names>S</given-names></name><name><surname>Dart</surname><given-names>JK</given-names></name></person-group><article-title>A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba keratitis</article-title><source>Invest Ophthalmol Vis Sci</source><year>1994</year><volume>35</volume><fpage>1059</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">8125716</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>J</given-names></name><name><surname>Kirkness</surname><given-names>CM</given-names></name><name><surname>Seal</surname><given-names>DV</given-names></name><name><surname>Wright</surname><given-names>P</given-names></name></person-group><article-title>Drug resistance and acanthamoeba keratitis: the quest for alternative antiprotozoal chemotherapy</article-title><source>Eye</source><year>1994</year><volume>8</volume><fpage>555</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">7835453</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacon</surname><given-names>AS</given-names></name><name><surname>Frazer</surname><given-names>DG</given-names></name><name><surname>Dart</surname><given-names>JK</given-names></name><name><surname>Matheson</surname><given-names>M</given-names></name><name><surname>Ficker</surname><given-names>LA</given-names></name><name><surname>Wright</surname><given-names>P</given-names></name></person-group><article-title>A review of 72 consecutive cases of Acanthamoeba keratitis</article-title><source>Eye</source><year>1993</year><volume>7</volume><fpage>719</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">8119418</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theng</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Ling</surname><given-names>ML</given-names></name></person-group><article-title>Microsporidial keratoconjunctivitis in a healthy contact lens wearer without human immunodeficiency virusinfection</article-title><source>Ophthalmology</source><year>2001</year><volume>108</volume><fpage>976</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11320030</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkins</surname><given-names>JH</given-names></name><name><surname>Joshi</surname><given-names>N</given-names></name><name><surname>Margolis</surname><given-names>TP</given-names></name><name><surname>Cevallos</surname><given-names>V</given-names></name><name><surname>Dawson</surname><given-names>CR</given-names></name></person-group><article-title>Microsporidial keratoconjunctivitis treated successfully with a short course of topical fumagillin</article-title><source>Eye</source><year>1994</year><volume>8</volume><fpage>703</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">7867837</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roseberger</surname><given-names>DF</given-names></name><name><surname>Serderavic</surname><given-names>ON</given-names></name><name><surname>Erlandson</surname><given-names>RA</given-names></name><name><surname>Bryan</surname><given-names>RT</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Visvesvara</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Successful treatment of microsporidial keratoconjunctivitis with topical fumagillin in a patient withAIDS</article-title><source>Cornea</source><year>1993</year><volume>12</volume><fpage>261</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8500340</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gritz</surname><given-names>DC</given-names></name><name><surname>Holsclaw</surname><given-names>DS</given-names></name><name><surname>Neger</surname><given-names>RE</given-names></name></person-group><article-title>Ocular and sinus microsporidial infection cured with systemic albendazole</article-title><source>Am J Ophthalmol</source><year>1997</year><volume>124</volume><fpage>241</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">9262551</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>P</given-names></name><name><surname>Urbani</surname><given-names>C</given-names></name><name><surname>Donelli</surname><given-names>G</given-names></name></person-group><article-title>Resolution of microsporidial sinusitis and keratoconjunctivitis by itraconazole treatment</article-title><source>Am J Ophthalmol</source><year>1999</year><volume>127</volume><fpage>210</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">10030568</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelmus</surname><given-names>KR</given-names></name><name><surname>Gee</surname><given-names>L</given-names></name><name><surname>Hauck</surname><given-names>WW</given-names></name><name><surname>Kurinij</surname><given-names>N</given-names></name><name><surname>Dawson</surname><given-names>CR</given-names></name><name><surname>Jones</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Herpetic eye disease study: A controlled trial of topical corticosteroids for herpes simplex stromalkeratitis</article-title><source>Ophthalmology</source><year>1994</year><volume>101</volume><fpage>1883</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">7997324</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barron</surname><given-names>BA</given-names></name><name><surname>Gee</surname><given-names>I</given-names></name><name><surname>Hauck</surname><given-names>WW</given-names></name><name><surname>Kurinij</surname><given-names>N</given-names></name><name><surname>Dawson</surname><given-names>CR</given-names></name><name><surname>Jones</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Herpetic eye disease study: A controlled trial of oral acyclovir for herpes simplex stromal keratitis</article-title><source>Ophthalmology</source><year>1994</year><volume>101</volume><fpage>1871</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">7997323</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><collab>The herpetic eye disease study group</collab><article-title>A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus</article-title><source>Arch Ophthalmol</source><year>1996</year><volume>114</volume><fpage>1065</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">8790090</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><collab>The herpetic eye disease study group</collab><article-title>Acyclovir for the prevention of recurrent herpes simplex virus eye disease</article-title><source>N Engl J Med</source><year>1998</year><volume>339</volume><fpage>300</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9696640</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beutner</surname><given-names>KR</given-names></name></person-group><article-title>Valacyclovir: A review of its antiviral activity, pharmacokinetic properties and clinical efficacy</article-title><source>Antiviral Res</source><year>1995</year><volume>28</volume><fpage>281</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">8669888</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kost</surname><given-names>RG</given-names></name><name><surname>Straus</surname><given-names>SE</given-names></name></person-group><article-title>Postherpetic neuralgia-pathogenesis, treatment and prevention</article-title><source>N Engl J Med</source><year>1996</year><volume>335</volume><fpage>32</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">8637540</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Comparison of fluoroquinolones and fortified eye drops</p></caption><alt-text>Table 1</alt-text><graphic xlink:href="IndianJOphthalmol-56-215-g001"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Empiric therapy - comparison of fluoroquinolones</p></caption><alt-text>Table 2</alt-text><graphic xlink:href="IndianJOphthalmol-56-215-g002"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Antifungals for fungal corneal ulcers</p></caption><alt-text>Table 3</alt-text><graphic xlink:href="IndianJOphthalmol-56-215-g003"/></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Antiamoebics for keratitis</p></caption><alt-text>Table 4</alt-text><graphic xlink:href="IndianJOphthalmol-56-215-g004"/></table-wrap></floats-group></article>